Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glutathione | 12 | 2023 | 200 | 3.400 |
Why?
|
| Acetylcysteine | 6 | 2023 | 82 | 3.090 |
Why?
|
| Glycine | 10 | 2023 | 162 | 2.860 |
Why?
|
| Insulin Resistance | 7 | 2023 | 698 | 1.700 |
Why?
|
| Cysteine | 5 | 2015 | 142 | 1.600 |
Why?
|
| HIV Infections | 11 | 2021 | 2050 | 1.290 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 6 | 2012 | 29 | 1.280 |
Why?
|
| Oxidative Stress | 7 | 2023 | 801 | 1.240 |
Why?
|
| Dietary Supplements | 8 | 2023 | 439 | 1.120 |
Why?
|
| Mitochondria | 8 | 2023 | 751 | 1.100 |
Why?
|
| Inflammation | 5 | 2023 | 1522 | 0.920 |
Why?
|
| Muscle Strength | 2 | 2021 | 86 | 0.840 |
Why?
|
| Healthy Aging | 1 | 2021 | 12 | 0.730 |
Why?
|
| Dyslipidemias | 3 | 2015 | 241 | 0.710 |
Why?
|
| Body Composition | 6 | 2021 | 550 | 0.660 |
Why?
|
| Diet | 4 | 2015 | 1125 | 0.620 |
Why?
|
| Diet Therapy | 2 | 2018 | 41 | 0.590 |
Why?
|
| Aging | 5 | 2023 | 1254 | 0.580 |
Why?
|
| Lipid Metabolism | 6 | 2013 | 382 | 0.530 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 315 | 0.530 |
Why?
|
| Lipodystrophy | 3 | 2006 | 33 | 0.480 |
Why?
|
| Cognition | 1 | 2021 | 811 | 0.470 |
Why?
|
| Hypolipidemic Agents | 5 | 2011 | 189 | 0.450 |
Why?
|
| Anti-HIV Agents | 2 | 2015 | 348 | 0.450 |
Why?
|
| Leptin | 2 | 2015 | 219 | 0.440 |
Why?
|
| Thiazolidinediones | 2 | 2015 | 81 | 0.430 |
Why?
|
| Exercise Therapy | 1 | 2015 | 183 | 0.400 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 239 | 0.380 |
Why?
|
| Energy Metabolism | 4 | 2012 | 784 | 0.380 |
Why?
|
| Fatty Acids | 2 | 2013 | 356 | 0.380 |
Why?
|
| Lipids | 2 | 2012 | 561 | 0.360 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 139 | 0.320 |
Why?
|
| Oxidation-Reduction | 6 | 2013 | 436 | 0.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2010 | 270 | 0.310 |
Why?
|
| Hormone Replacement Therapy | 1 | 2012 | 211 | 0.310 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2015 | 116 | 0.300 |
Why?
|
| Triglycerides | 3 | 2015 | 617 | 0.300 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 516 | 0.300 |
Why?
|
| Niacin | 3 | 2015 | 59 | 0.260 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 482 | 0.250 |
Why?
|
| Lipolysis | 4 | 2010 | 75 | 0.250 |
Why?
|
| Metabolic Syndrome | 2 | 2008 | 365 | 0.240 |
Why?
|
| Mice | 8 | 2024 | 18507 | 0.240 |
Why?
|
| Age Factors | 4 | 2021 | 2923 | 0.240 |
Why?
|
| Nelson Syndrome | 1 | 2005 | 2 | 0.240 |
Why?
|
| Humans | 30 | 2024 | 132247 | 0.240 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2005 | 74 | 0.230 |
Why?
|
| Cholesterol, LDL | 3 | 2015 | 606 | 0.230 |
Why?
|
| Human Growth Hormone | 3 | 2015 | 75 | 0.220 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 46 | 0.220 |
Why?
|
| Hypertriglyceridemia | 1 | 2005 | 114 | 0.210 |
Why?
|
| Immune Tolerance | 1 | 2024 | 153 | 0.210 |
Why?
|
| Dietary Fats | 1 | 2005 | 279 | 0.210 |
Why?
|
| Animals | 11 | 2024 | 34850 | 0.210 |
Why?
|
| Palmitates | 3 | 2013 | 17 | 0.200 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 306 | 0.200 |
Why?
|
| Aged | 6 | 2023 | 21482 | 0.190 |
Why?
|
| Hyperthyroidism | 1 | 2001 | 24 | 0.180 |
Why?
|
| Glycine Agents | 1 | 2021 | 10 | 0.180 |
Why?
|
| Cholesterol, HDL | 2 | 2015 | 398 | 0.170 |
Why?
|
| Body Weight | 1 | 2005 | 995 | 0.170 |
Why?
|
| HIV-1 | 3 | 2013 | 484 | 0.170 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 95 | 0.170 |
Why?
|
| Spinal Fractures | 1 | 2001 | 46 | 0.170 |
Why?
|
| Free Radical Scavengers | 1 | 2021 | 58 | 0.170 |
Why?
|
| Endothelium | 1 | 2021 | 64 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2010 | 1418 | 0.170 |
Why?
|
| Gene Products, vpr | 2 | 2013 | 18 | 0.170 |
Why?
|
| Male | 19 | 2021 | 65012 | 0.170 |
Why?
|
| Longevity | 1 | 2022 | 159 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2024 | 413 | 0.170 |
Why?
|
| Fatigue | 1 | 2021 | 201 | 0.160 |
Why?
|
| Obesity | 1 | 2012 | 2398 | 0.160 |
Why?
|
| Osteoporosis | 1 | 2001 | 138 | 0.160 |
Why?
|
| Lactation | 1 | 2001 | 198 | 0.160 |
Why?
|
| Neutropenia | 1 | 2001 | 205 | 0.160 |
Why?
|
| Perception | 1 | 2021 | 236 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 192 | 0.160 |
Why?
|
| Health Promotion | 1 | 2023 | 399 | 0.150 |
Why?
|
| Middle Aged | 11 | 2015 | 29021 | 0.150 |
Why?
|
| Nutrition Disorders | 1 | 1998 | 29 | 0.150 |
Why?
|
| Fenofibrate | 2 | 2011 | 61 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 4758 | 0.150 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 27 | 0.150 |
Why?
|
| Body Temperature Regulation | 1 | 1998 | 50 | 0.150 |
Why?
|
| Tuberculosis | 1 | 2024 | 556 | 0.140 |
Why?
|
| DNA Damage | 1 | 2021 | 511 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2024 | 1122 | 0.140 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 199 | 0.130 |
Why?
|
| Blood Glucose | 2 | 2012 | 1121 | 0.130 |
Why?
|
| Glycerol | 2 | 2010 | 82 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1249 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1444 | 0.130 |
Why?
|
| Adult | 9 | 2021 | 31614 | 0.130 |
Why?
|
| Life Style | 3 | 2011 | 453 | 0.130 |
Why?
|
| Genome, Fungal | 1 | 2016 | 34 | 0.120 |
Why?
|
| Candida tropicalis | 1 | 2016 | 17 | 0.120 |
Why?
|
| Cardiovascular Diseases | 3 | 2008 | 2087 | 0.120 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2015 | 12 | 0.120 |
Why?
|
| Fungal Proteins | 1 | 2016 | 135 | 0.120 |
Why?
|
| Fibric Acids | 1 | 2015 | 7 | 0.120 |
Why?
|
| Antioxidants | 2 | 2018 | 333 | 0.110 |
Why?
|
| Azetidines | 1 | 2015 | 64 | 0.110 |
Why?
|
| Pyrazines | 1 | 2015 | 72 | 0.110 |
Why?
|
| Ezetimibe | 1 | 2015 | 94 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2015 | 74 | 0.110 |
Why?
|
| Genomics | 1 | 2022 | 1652 | 0.100 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 188 | 0.100 |
Why?
|
| Mass Spectrometry | 2 | 2016 | 356 | 0.100 |
Why?
|
| Cholesterol, VLDL | 1 | 2013 | 18 | 0.100 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 106 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 666 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 464 | 0.100 |
Why?
|
| Isotopes | 1 | 2011 | 25 | 0.090 |
Why?
|
| F2-Isoprostanes | 1 | 2011 | 21 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2012 | 1653 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2161 | 0.090 |
Why?
|
| Global Health | 1 | 2016 | 643 | 0.090 |
Why?
|
| Chromatography, Thin Layer | 2 | 2013 | 45 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2011 | 181 | 0.080 |
Why?
|
| Calorimetry, Indirect | 1 | 2010 | 61 | 0.080 |
Why?
|
| Adiponectin | 1 | 2011 | 128 | 0.080 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 59 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2011 | 201 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 128 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 147 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 150 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 7138 | 0.080 |
Why?
|
| Female | 10 | 2021 | 70785 | 0.080 |
Why?
|
| Syndrome | 2 | 2002 | 1175 | 0.070 |
Why?
|
| Glucose | 1 | 2013 | 871 | 0.070 |
Why?
|
| Kinetics | 1 | 2010 | 1130 | 0.070 |
Why?
|
| Carbon Isotopes | 2 | 2006 | 233 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 742 | 0.070 |
Why?
|
| Exercise | 3 | 2011 | 860 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2005 | 3414 | 0.060 |
Why?
|
| Esterification | 2 | 2006 | 13 | 0.060 |
Why?
|
| Young Adult | 1 | 2021 | 9966 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 1037 | 0.060 |
Why?
|
| Diet, Fat-Restricted | 1 | 2006 | 40 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2005 | 29 | 0.060 |
Why?
|
| Chylomicrons | 1 | 2005 | 9 | 0.060 |
Why?
|
| Health Behavior | 1 | 2008 | 398 | 0.060 |
Why?
|
| Adipocytes | 2 | 2006 | 182 | 0.060 |
Why?
|
| Postprandial Period | 1 | 2005 | 91 | 0.060 |
Why?
|
| Succinates | 1 | 2024 | 19 | 0.060 |
Why?
|
| Succinic Acid | 1 | 2024 | 13 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2005 | 321 | 0.060 |
Why?
|
| Fasting | 2 | 2003 | 302 | 0.060 |
Why?
|
| Everolimus | 1 | 2024 | 50 | 0.050 |
Why?
|
| Cicatrix | 1 | 2005 | 121 | 0.050 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 275 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 2006 | 510 | 0.050 |
Why?
|
| Viral Load | 1 | 2005 | 408 | 0.050 |
Why?
|
| Prognosis | 2 | 2004 | 5016 | 0.050 |
Why?
|
| Leucine | 1 | 2003 | 260 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 899 | 0.050 |
Why?
|
| Methimazole | 1 | 2001 | 6 | 0.050 |
Why?
|
| Propylthiouracil | 1 | 2001 | 8 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2001 | 75 | 0.040 |
Why?
|
| Prevalence | 2 | 2008 | 2664 | 0.040 |
Why?
|
| Organ Size | 1 | 2002 | 447 | 0.040 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2001 | 41 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2001 | 58 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2001 | 249 | 0.040 |
Why?
|
| Reference Values | 1 | 2002 | 703 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2002 | 239 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2001 | 113 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 755 | 0.040 |
Why?
|
| Neutrophils | 1 | 2001 | 360 | 0.040 |
Why?
|
| Comorbidity | 1 | 2004 | 1610 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 337 | 0.040 |
Why?
|
| Bone Density | 1 | 2001 | 370 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 547 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2018 | 201 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1998 | 699 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 83 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 3093 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 1966 | 0.030 |
Why?
|
| Disease Progression | 1 | 2001 | 2233 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 2451 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2004 | 3736 | 0.030 |
Why?
|
| Maze Learning | 1 | 1994 | 104 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 1233 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 58 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2013 | 55 | 0.030 |
Why?
|
| Mental Recall | 1 | 1994 | 143 | 0.030 |
Why?
|
| Electroconvulsive Therapy | 1 | 1994 | 82 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2013 | 89 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 302 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 826 | 0.020 |
Why?
|
| Liver | 2 | 2006 | 1797 | 0.020 |
Why?
|
| Pregnancy | 1 | 2001 | 7557 | 0.020 |
Why?
|
| India | 1 | 2008 | 238 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 12 | 0.020 |
Why?
|
| Apolipoprotein B-100 | 1 | 2006 | 38 | 0.020 |
Why?
|
| Calorimetry | 1 | 2006 | 63 | 0.020 |
Why?
|
| Deuterium | 1 | 2006 | 93 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 408 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 308 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 140 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2001 | 14736 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 1354 | 0.010 |
Why?
|
| Adolescent | 1 | 2001 | 20557 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 1294 | 0.010 |
Why?
|
| HIV | 1 | 2004 | 190 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2003 | 120 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1563 | 0.010 |
Why?
|
| Risk Factors | 2 | 2008 | 10945 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 1365 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 1338 | 0.010 |
Why?
|
| Homeostasis | 1 | 2003 | 722 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 13027 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 6451 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 4690 | 0.010 |
Why?
|
| United States | 1 | 2008 | 11669 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1224 | 0.010 |
Why?
|
| Rats | 1 | 1994 | 3607 | 0.000 |
Why?
|